All
Relatives of Patients With Myeloid Blood Cancers May be at Two-Fold Risk for Disease
August 14th 2018Recent research showed first-degree relatives of patients with certain types of blood cancers may be at an increased risk for such disease, highlighting the importance of counseling, gene testing and surveillance.
FDA Grants Elzonris a Priority Review to Treat a Rare Blood Cancer
August 14th 2018The FDA has granted a priority review designation to a biologics license application (BLA) for SL-401 (tagraxofusp, Elzonris) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to Stemline Therapeutics, the developer of the novel stemness inhibitor.
Tumor Treating Fields Plus Paclitaxel Appears Safe, Effective in Recurrent Ovarian Cancer
August 13th 2018The combination use of Tumor Treating Fields plus paclitaxel more than doubled progression-free survival, with no serious treatment-related side effects in women with recurrent, platinum-resistant ovarian cancer.
Patient Awarded $289 Million in Landmark Monsanto-Associated Cancer Case
August 13th 2018Dewayne Johnson, a patient with cancer who claimed that Monsanto’s Roundup product was at the root of his non-Hodgkin lymphoma diagnosis in 2014, was awarded $289 million by a jury, as reported by the Associated Press.
Triplet Gets Breakthrough Therapy Designation in Colorectal Cancer
August 8th 2018The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovi (binimetinib), and the EGFR inhibitor Erbitux (cetuximab) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC) following one or two prior lines of treatment in the metastatic setting.